Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology's CMO, Dr. Charlie Morris
Source: Cell & Gene
![22_01_cgpodcast_1200x628_ep21 22_01_cgpodcast_1200x628_ep21](https://vertassets.blob.core.windows.net/image/3715921a/3715921a-426b-4000-8247-f8019d5975f7/375_250-22_01_cgpodcast_1200x628_ep21.png)
Celyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a non-gene edited shRNA approach may result in better efficacy and safety for CAR-T therapies.
This website uses cookies to ensure you get the best experience on our website. Learn more